Drug Trial Radar · NCT00829166
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
991
Actual
Start
Feb 2009
Primary completion
Jul 2012
Study completion Sep 2015
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.
Conditions
- Breast Cancer
Interventions
Trastuzumab emtansineDrug
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
LapatinibDrug
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
CapecitabineDrug
Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
- Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
- Percentage of Participants Who Died: Second Interim AnalysisTime frame: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
- Overall Survival: Second Interim Analysis (Co-primary Endpoint)Time frame: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
- Percentage of Participants Who Died: Final AnalysisTime frame: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
- Overall Survival: Final AnalysisTime frame: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
- Percentage of Participants Who Were Alive at Year 1Time frame: Year 1
- Percentage of Participants Who Were Alive at Year 2Time frame: Year 2
Locations
323 sites in 27 countries. Site status is shown where the registry gives one.
Site not named
Chandler, Arizona
Site not named
Tucson, Arizona
Site not named
Anaheim, California
Site not named
Anaheim, California
Site not named
Bakersfield, California
Site not named
Baldwin Park, California
Site not named
Bellflower, California
Site not named
Duarte, California
Site not named
Fontana, California
Site not named
Hayward, California
Site not named
Irvine, California
Site not named
La Jolla, California
Site not named
La Mesa, California
Site not named
Loma Linda, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Montebello, California
Site not named
Newport Beach, California
Site not named
Oakland, California
Site not named
Panorama City, California
Site not named
Riverside, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Jose, California
Site not named
Santa Clara, California
Site not named
Santa Maria, California
Site not named
Santa Monica, California
Site not named
South San Francisco, California
Site not named
Thousand Oaks, California
Site not named
Vallejo, California
Site not named
Walnut Creek, California
Site not named
Woodland Hills, California
Site not named
Fort Collins, Colorado
Site not named
Norwalk, Connecticut
Showing 40 of 323 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.